{
  "ticker": "JNJ",
  "target_date": "2025-07-10",
  "actual_date": "2025-07-10",
  "collected_at": "2025-12-08T11:59:52.420102",
  "price": {
    "open": 153.98,
    "high": 157.08,
    "low": 153.71,
    "close": 155.5533447265625,
    "volume": 6732900,
    "change_1d_pct": 0.9,
    "change_7d_pct": 3.23,
    "change_30d_pct": 2.9
  },
  "technicals": {
    "rsi_14": 80.05,
    "sma_20": 152.04,
    "sma_50": 151.32,
    "macd": 0.839,
    "macd_signal": 0.418,
    "macd_histogram": 0.421,
    "bb_upper": 156.7,
    "bb_lower": 147.39,
    "price_vs_sma20_pct": 2.31,
    "price_vs_sma50_pct": 2.8,
    "volume_ratio": 0.84
  },
  "fundamentals": {
    "market_cap": 489520562176,
    "pe_ratio": 19.611969,
    "forward_pe": 19.167923,
    "price_to_book": 6.166874,
    "price_to_sales": 5.312272,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.23,
    "pct_from_52w_low": 44.43
  },
  "macro": {
    "spy": {
      "price": 624.09,
      "change_1d_pct": 0.28,
      "change_7d_pct": 1.32
    },
    "vix": {
      "level": 15.78,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.35
    },
    "dollar_index": {
      "level": 97.65
    },
    "gold": {
      "price": 3317.4
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data",
      "source": "Yahoo",
      "datetime": 1752162025,
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced the submission of a supplemental New Drug Application/sNDA to the US FDA for its schizophrenia drug called CAPLYTA (lumateperone). The submission is based on long-term Phase 3 c",
      "url": "https://finnhub.io/api/news?id=3d81316f9f3132daac3a9038ee9af5d5d319bd9d7745399a5727d1fb93698c6f"
    },
    {
      "headline": "UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT",
      "source": "Yahoo",
      "datetime": 1752160442,
      "summary": "Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 25, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) and set a price target of DKK2,500.00. The company reported $715 million in revenue for the first three months of 2025 c",
      "url": "https://finnhub.io/api/news?id=d00c2451e58b9a7164d140f06be9a4efeca2dd70938cad20163b91569ccb6a42"
    },
    {
      "headline": "Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump",
      "source": "Yahoo",
      "datetime": 1752154440,
      "summary": "Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.",
      "url": "https://finnhub.io/api/news?id=df287e40eb727c86c9092cf435149978e345a0469131169198519a9fb2846e4e"
    },
    {
      "headline": "Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?",
      "source": "Yahoo",
      "datetime": 1752150300,
      "summary": "HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.",
      "url": "https://finnhub.io/api/news?id=97aaa85da616b95705eb608d25bf7c5d2cb0bea0dbca2dba389095a9a3536b09"
    },
    {
      "headline": "These Are The Most Overvalued And Undervalued Mega Cap Stocks",
      "source": "SeekingAlpha",
      "datetime": 1752144489,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5d1188996de610d85b617148b91a54f4e10a95dc28b96e263ef778afb7ab47a9"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760229.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000154/xslF345X05/wk-form4_1749760229.xml"
    },
    {
      "form": "8-K",
      "date": "2025-06-10",
      "description": "jnj-20250610.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000152/jnj-20250610.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}